Citation tools

Tóth, Gábor et al "Abstract B069: The best is not enough—when it is alone: Current clinical doses of humanized anti-Her2 antibodies should be applied in combination to delay development of trastuzumab resistance by additively enhancing ADCC." Cancer Immunology Research 4.11 Supplement (2016): B069. Web. 20 Oct. 2019.